Oruka Therapeutics (ORKA) News Today $20.31 -0.45 (-2.17%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Takes $17.66 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Franklin Resources Inc. purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 720,547 sDecember 21 at 4:46 AM | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Oruka Therapeutics (ORKA) and Adicet Bio (ACET)December 20 at 7:34 PM | markets.businessinsider.comOruka Therapeutics’s ORKA-001: Promising Psoriasis Treatment Drives Buy Rating with 12-Month Price Target of $45December 20 at 7:34 PM | markets.businessinsider.comOruka Therapeutics doses first participants in Phase 1 trial of ORKA-001December 20 at 9:32 AM | finance.yahoo.comOruka Therapeutics (NASDAQ:ORKA) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday.December 20 at 8:31 AM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 4.7% - What's Next?Oruka Therapeutics (NASDAQ:ORKA) Trading Down 4.7% - Should You Sell?December 19 at 1:47 PM | marketbeat.comOruka Therapeutics, Inc.: Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)December 19 at 10:33 AM | finanznachrichten.deOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyDecember 19 at 7:00 AM | globenewswire.comWellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Wellington Management Group LLP bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 82,137 shares of the company'December 19 at 3:33 AM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) & Lantheus (NASDAQ:LNTH) Head-To-Head SurveyDecember 19 at 2:47 AM | americanbankingnews.comOruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)December 18, 2024 | globenewswire.comOruka Therapeutics (NASDAQ:ORKA) Sees Large Volume Increase - Should You Buy?Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading Volume - Here's What HappenedDecember 16, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 42,298 shares of the company'sDecember 13, 2024 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%December 11, 2024 | finance.yahoo.comOruka Therapeutics (ORKA) Gets a Buy from TD CowenDecember 11, 2024 | markets.businessinsider.comPromising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis TreatmentDecember 10, 2024 | markets.businessinsider.comFrazier Life Sciences Management L.P. Purchases New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Frazier Life Sciences Management L.P. acquired a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 477,327 shares of the company's stock, valued at approxiDecember 10, 2024 | marketbeat.comJanus Henderson Group PLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Janus Henderson Group PLC acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 236,116 shares of the company's stock, valued at approximately $5,840,December 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Point72 Asset Management L.P. purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 482,330 shares of the company's stock, valued at approximaDecember 8, 2024 | marketbeat.comRTW Investments LP Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)RTW Investments LP acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,850,648 shares of the company's stock, valued at approximately $45,359,000. RTW Investments LPDecember 5, 2024 | marketbeat.comRedmile Group LLC Acquires New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Redmile Group LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 411,728 shares of the company's stock, valued at approximately $10,091,000. Redmile GroupDecember 5, 2024 | marketbeat.comFmr LLC Purchases Shares of 4,682,300 Oruka Therapeutics, Inc. (NASDAQ:ORKA)Fmr LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,682,300 shares of the company's stock, valued at apprDecember 5, 2024 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Buy" by BrokeragesOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received a consensus rating of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommDecember 2, 2024 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Up 7.4% - Here's WhyOruka Therapeutics (NASDAQ:ORKA) Trading Up 7.4% - Time to Buy?November 29, 2024 | marketbeat.comBraidwell LP Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Braidwell LP purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 515,726 shares of the company's stock, valued at approximately $12,640,000. BraidwelNovember 29, 2024 | marketbeat.comGreat Point Partners LLC Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Great Point Partners LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 514,659 shares of the company's stock, valued at approximately $12,6November 27, 2024 | marketbeat.comResearch Analysts Issue Forecasts for ORKA FY2024 EarningsOruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - HC Wainwright decreased their FY2024 EPS estimates for Oruka Therapeutics in a report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.24) for the year, downNovember 27, 2024 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday.November 25, 2024 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading Volume - Should You Buy?Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading Volume - What's Next?November 22, 2024 | marketbeat.comOruka Therapeutics gains approval for preferred stock conversionNovember 20, 2024 | investing.comPositive Outlook for Oruka Therapeutics Driven by Innovative Pipeline and Financial StabilityNovember 20, 2024 | markets.businessinsider.comWedbush Initiates a Buy Rating on Oruka Therapeutics (ORKA)November 19, 2024 | markets.businessinsider.comOruka Therapeutics’ Promising Long-Term Strategy and Advancements in Psoriasis Treatments Drive Buy RatingNovember 19, 2024 | markets.businessinsider.comOruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 16, 2024 | finanznachrichten.deStrong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug PipelineNovember 15, 2024 | markets.businessinsider.comPositive Outlook for Oruka Therapeutics: Promising Developments with ORKA-001November 14, 2024 | markets.businessinsider.comOruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comOruka Therapeutics to Present at Multiple November Investor ConferencesNovember 4, 2024 | globenewswire.comPromising Prospects of ORKA-001 in the IL-23p19 Inhibitor Market: A Buy RecommendationNovember 1, 2024 | markets.businessinsider.comBuy Rating on Oruka Therapeutics for Innovative Psoriasis Treatments with Market-Leading PotentialOctober 11, 2024 | markets.businessinsider.comBuy Rating on Oruka Therapeutics Backed by ORKA-001’s Promising Preclinical Data and Dosing AdvantageSeptember 28, 2024 | markets.businessinsider.comBuy Rating on Oruka Therapeutics’ ORKA-001 for Extended Dosing and Market PotentialSeptember 26, 2024 | markets.businessinsider.comOruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressSeptember 25, 2024 | globenewswire.comOruka Therapeutics Inc ORKASeptember 19, 2024 | morningstar.comOruka Therapeutics Poised for Outperformance with Innovative Psoriasis TreatmentsSeptember 18, 2024 | markets.businessinsider.comBuy Rating on Oruka Therapeutics: Promising Developments in Long-Acting Dermatological and Rheumatologic TreatmentsSeptember 16, 2024 | markets.businessinsider.comInnovative Antibody Engineering Positions Oruka Therapeutics for Market SuccessSeptember 16, 2024 | markets.businessinsider.comBiotech firm enters $200M agreementSeptember 12, 2024 | bizjournals.comOruka Therapeutics announces $200M private financingSeptember 12, 2024 | msn.comOruka Therapeutics Announces $200 Million Private PlacementSeptember 12, 2024 | tmcnet.com Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << ORKA Media Mentions By Week ORKA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORKA News Sentiment▼0.460.60▲Average Medical News Sentiment ORKA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORKA Articles This Week▼133▲ORKA Articles Average Week Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QDEL News Today NEOG News Today CLDX News Today NTLA News Today MYGN News Today TKNO News Today ACHV News Today VNRX News Today CDIO News Today ICCC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORKA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
